CytomX Therapeutics (CTMX) 10-K 2021 FY Annual report

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statements (Form S-3 No. 333-216567, 333-228203 and 333-258510) and related prospectuses of CytomX Therapeutics, Inc., and

(2)

Registration Statements (Form S-8 No. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916, 333-236711, 333-253452 and 333-255832) pertaining to the 2015 Equity Incentive Plan, the Employee Stock Purchase Plan and the 2019 Employment Inducement Incentive Plan, of CytomX Therapeutics, Inc.;

of our reports dated March 1, 2022, with respect to the financial statements of CytomX Therapeutics, Inc., and the effectiveness of internal control over financial reporting of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) of CytomX Therapeutics Inc., for the year ended December 31, 2021.

/s/ Ernst & Young LLP

Redwood City, California

March 1, 2022